Calvin A. Wallen, III is the Chairman of the Board of Venturis Therapeutics and has served in that capacity since June 2013. Mr. Wallen became an investor in the company in 2009 and since that time has supported a considerable amount of financial needs. Mr. Wallen has over 35 years of experience in the upstream oil and gas industry working as a drilling and petroleum engineer while also serving in high level management and as a director with several companies. He has been an active investor in several sectors of business and industry for over 15 years in the US. Mr. Wallen is an active member of several professional associations and attended Texas A&M University.

Robert Schleizer has served on the Board of Venturis Therapeutics since June 2013. Mr. Schleizer has over thirty years of financial and operational experience serving private and public companies in financial and organizational restructuring, crisis management, acquisitions and divestitures, and equity and debt financings. Mr. Schleizer is a co-founder and Managing Director of BlackBriar Advisors LLC, a financial and operational advisory firm. Prior to the founding of BlackBriar in December 2010, Mr. Schleizer served as Managing Director of BBK, Ltd. an international financial advisory firm, from June 2009 until December 2010. Prior to BBK, Mr. Schleizer was a partner from 1999 to 2009 in Tatum LLC, a national consulting firm providing CFO Services where served as Restructuring Practice Leader in the Southwest region. Mr. Schleizer holds a Bachelor of Science degree in Accounting from Arizona State University.

Ms. Elvia Gustavson was appointed Head of Regulatory Affairs in July 2017. Ms. Gustavson has over 30 years of experience in the pharmaceutical industry working on injectables, solid oral dosage forms, small molecule and biological drugs. She has held senior management positions at mid-size and small pharmaceutical companies. Additionally, she has provided regulatory support to pharmaceutical companies as a Regulatory Affairs Consultant with Jeff Yuen & Associates, Inc.

As a Regulatory Affairs professional, she has been instrumental in providing regulatory strategies and solutions throughout the life cycle of drug product development including R&D development, clinical studies, drug application, commercialization, and post marketing. These endeavors have led to the filings of numerous applications (i.e., BLAs, ANDAs & INDs). Ms. Gustavson received her B.S. from the San Diego State University in Microbiology.

Dr. Sherman earned his Bachelor of Science from MIT and Doctorate in Medicine from SUNY Upstate Medical Center in 1977. Following an internal medicine residency in Rochester, NY and cardiovascular fellowship at Oregon Health Sciences University, he joined the faculty of Mount Sinai in NY in 1983 and, with deepening interests in regenerative cardiology, of Columbia University Medical Center in 2005. As Associate Professor and Director of Stem Cell Research and Regenerative Medicine in the Center for Interventional Vascular Therapies, his research focused on delivery methods of biotherapeutics for chronic CAD, STEMI and HF, including several first-in-human studies. He was Director of the annual International Conference on Cell Therapy for Cardiovascular Diseases (IC3D) and consultant to NIH, CIRM, Canada Foundation for Innovation (Networks of Centres of Excellence, NCE) European Society of Cardiology and biotechnology companies, specializing in the discovery and development of regenerative, protective and reconstructive therapies.

In 2014 he transitioned to industry and has been Chief Medical Officer of Celyad, LoneStar Heart and Black Beret Life Sciences before joining Venturis Therapeutics.

David M. Ornitz is Alumni Endowed Professor in the Department of Developmental Biology at Washington University School of Medicine. His research uses molecular, genetic and biochemical approaches to study the regulation of cell growth, development, response to injury, and cancer. Current studies are examining FGFs, FGF receptors and a variety of other interacting signaling pathways (hedgehog, Wnt, BMP, TGFβ, VEGF) in the mouse embryo and in adult mice, with a focus on inner ear, skeletal, cardiovascular and pulmonary development and physiology. Using conditional knockout and conditional gene activation technology the Ornitz laboratory studies FGF signaling pathways in these and other organ systems. Mutant mice are being studied as genetic and developmental model systems for mesodermal and epithelial patterning, organogenesis, tissue repair and regeneration, and cancer.

Arnold I. Chin, M.D., Ph.D., is an Associate Professor of Urology at the David Geffen School of Medicine at UCLA. Dr. Chin graduated from Princeton University in 1995 with a Bachelor of Arts in Chemistry. He then went on to complete both his MD and PhD at UCLA, earning a Doctor of Philosophy in Molecular Biology in 2002. He completed his Doctor of Medicine in 2003 and his residency in Urology at UCLA in 2009. He then joined the faculty in the Department of Urology at UCLA as an Assistant Professor and was tenured as an Associate Professor in 2016. Dr. Chin is a surgeon-scientist who has an active clinical practice in urologic oncology as well as leads an independent laboratory at the UCLA Broad Stem Cell Research Center. Dr. Chin’s laboratory research centers on the study of the tumor microenvironment in bladder and prostate cancer. His studies have led to an investigator initiated clinical trial. The laboratory’s long term goals are to develop novel therapeutic targets, immune-based platforms, and stem cell-directed therapies against cancer. Dr. Chin is also the Medical Director of the Clark Urology Clinic at UCLA, which has a robust program for the management of erectile dysfunction.